2-甲基-2,3-二氢苯并呋喃-2-羧酸 | 93885-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2-甲基-2,3-二氢苯并呋喃-2-羧酸
• 英文名称: 2-methyl-2,3-dihydrobenzofuran-2-carboxylic acid
• 英文别名: 2-methyl-3H-1-benzofuran-2-carboxylic acid
• CAS: 93885-44-0
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: MTVMBYHIKUWTPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-2,3-二氢苯并呋喃-2-羧酸 在 氯化亚砜 、 氨 、 sodium methylate 、 phosphorus pentoxide 作用下， 以 1,4-二氧六环 、 甲苯 、 苯 为溶剂， 反应 8.75h， 生成 2-(2-methyl-3H-1-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003
• 作为产物：
  描述：

  甲烯丙基苯醚 在 jones' reagent 、 Kieselgel 60 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 96.17h， 生成 2-甲基-2,3-二氢苯并呋喃-2-羧酸
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003

文献信息

• Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180244640A1

  公开（公告）日：2018-08-30

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予本发明化合物治疗囊性纤维化的方法。
• Imidazoline derivatives as presynaptic .alpha..sub.2 -adrenoreceptor
  申请人：Reckitt & Colman Products Limited

  公开号：US04411908A1

  公开（公告）日：1983-10-25

  Imidazoline derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen or alkyl C.sub.1-6 ; R.sup.2 is hydrogen, methyl, chloro, bromo or fluoro; R.sup.3 is hydrogen, methyl, hydroxy, methoxy, fluoro, chloro or bromo; and their non-toxic salts. Processes for their preparation and pharmaceutical compositions thereof. The compounds exhibit presynaptic .alpha..sub.2 -adrenoreceptor antagonist activity.

  咪唑啉衍生物的化学式为##STR1##其中R.sup.1为氢或烷基C.sub.1-6；R.sup.2为氢、甲基、氯、溴或氟；R.sup.3为氢、甲基、羟基、甲氧基、氟、氯或溴；以及它们的无毒盐。它们的制备方法和药物组合物。这些化合物具有前突触α2-肾上腺素受体拮抗活性。
• Bicyclic amides
  申请人：Castonguay A. Laurie

  公开号：US20050203112A1

  公开（公告）日：2005-09-15

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物为大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。
• Imidazoline derivatives
  申请人：RECKITT AND COLMAN PRODUCTS LIMITED

  公开号：EP0071368A1

  公开（公告）日：1983-02-09

  Imidazoline derivatives of the formula wherein R' is hydrogen or alkyl C1-6; R2 is hydrogen, methyl, chloro, bromo or fluoro; R3 is hydrogen, methyl, hydroxy, methoxy, fluoro, chloro or bromo; and their non-toxic salts. Processes for their preparation and pharmaceutical compositions thereof. The compounds exhibit presynaptic α2-adrenoreceptor antagonist activity.

  式中R'为氢或C1-6烷基；R2为氢、甲基、氯、溴或氟；R3为氢、甲基、羟基、甲氧基、氟、氯或溴的咪唑啉衍生物及其无毒盐。 其制备方法及其药物组合物。 这些化合物具有突触前α2-肾上腺素受体拮抗剂活性。
• Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
  申请人：AbbVie S.à.r.l.

  公开号：US10428017B2

  公开（公告）日：2019-10-01

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明涉及治疗囊性纤维化的化合物及其用途、生产方法、包含本发明化合物的药物组合物，以及通过施用本发明化合物治疗囊性纤维化的方法。